Table 2.

Characteristics associated with 5-year transplant-free survival by Cox regression analysis in patients with primary sclerosing cholangitis

Parameter	Univariate model		Multivariate model
	HR (95% CI)	p-value	HR (95% CI)	p-value
Sarcopenia via L3-SMI	5.561 (2.346–13.182)	< 0.001	2.749 (1.118–6.758)	0.028
Sex	0.607 (0.307–1.198)	0.150
Age	1.009 (0.988–1.032)	0.400
BMI	1.015 (0.982–1.048)	0.377
PSC-IBD	0.838 (0.451–1.559)	0.577
Liver cirrhosis	10.870 (4.714–25.070)	< 0.001
Malignancy	1.457 (0.736–2.883)	0.280
Dominant Stenosis	2.930 (1.359–6.317)	0.006	1.237 (0.516–2.961)	0.634
Ascites	6.528 (3.426–12.442)	< 0.001
Hepatic Encephalopathy	2.175 (1.074–4.405)	0.031
Splenomegaly	2.948 (1.581–5.498)	< 0.001	2.473 (1.203–5.087)	0.014
BMI reduction > 10% in 12 months	3.106 (1.636–5.894)	< 0.001	1.417 (0.703–2.856)	0.330
Recurring cholangitis (≥ 2x/6 months)	2.711 (1.424–5.161)	0.002	2.529 (1.190–5.376)	0.016
SEG	3.860 (2.122–7.021)	< 0.001
MELD score	1.121 (1.088–1.156)	< 0.001
Child-Pugh Grade	3.727 (2.302–6.036)	< 0.001
Mayo risk score	1.589 (1.325–1.905)	< 0.001
EASL 2022 CPG risk stratification	3.904 (1.396–10.919)	0.009
Platelets	0.997 (0.994–0.999)	0.015
Albumin	0.419 (0.307–0.571)	< 0.001
Bilirubin	1.114 (1.078–1.151)	< 0.001	1.079 (1.023–1.137)	0.005
INR	4.497 (2.720–7.435)	< 0.001	1.560 (0.673–3.617)	0.300
Creatinine	1.567 (1.018–2.411)	0.041
Sodium	0.894 (0.852–0.938)	< 0.001
Mode of cross-sectional imaging	0.342 (0.173–0.675)	0.002
SMI	0.973 (0.943–1.004)	0.083

Abbreviations: BMI, body mass index; EASL 2022 CPG, European Association for the Study of the Liver 2022 Clinical Practice Guidelines; INR, international normalized ratio; LTX, liver transplantation; MELD, Model of End-Stage Liver Disease; PSC-IBD, patient with primary sclerosing cholangitis and associated inflammatory bowel disease: SEG, Standard Exception criteria of Germany; SMI, skeletal muscle index